KDM4A and central nervous system cancer: Taken together, with its high-affinity inhibitory effect on JMJD2A and robust anti-proliferative activity against glioma cells factored in, these findings strongly highlight methylstat’s significant potential as a promising therapeutic agent for glioma treatment.